Under 10% of individuals that would benefit from weight-loss injections such as Wegovy are able to get them, caution the global health agency as it publishes its initial advice on the medications.
Given over a billion individuals worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
Per forecasts, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that obesity is a chronic disease that can be addressed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to widespread availability to the injections that can help people shift considerable body mass, says the agency.
Skinny Jab Supply Crisis
Even under the current most favorable case, the production of such drugs could only cover approximately 100 million people – under 10% of the global need, as stated by the health organization.
The guideline urges governments and firms to increase availability, through measures such as patent sharing.
The intellectual property rights on the active ingredient – the core component of a leading brand – is set to lapse in several nations in 2026.
The Way Obesity Drugs Operate
These medications replicate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so users reduce food intake.
Patients commonly see weight reduction in the initial weeks of beginning the regular doses.
Evidence suggests users may regain a significant portion a year later of stopping the drug, because their typical appetite return.
To be carrying excess weight elevates your likelihood for developing diseases, including diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight affects people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
